Jean-Francois Dierick

Dr. Jean-Francois Dierick

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in Open Research Europe
Verified
Journal Article
Open access
JDJean-Francois Dierick
Jean-Francois Dierick
MHMarlies Halder
Marlies Halder
CJCarmen Jungbaeck
Carmen Jungbaeck
JLJulie Lorenz
Julie Lorenz
JPJean-Marie Préaud
Jean-Marie Préaud
JVJoris Vandeputte
Joris Vandeputte
The aim of this letter is to share the discussions and proposals made by the VAC2VAC consortium on how to support the deployment of the “Consistency Approach” for quality control of established vaccines and thus facilitate the substitution of in vivo testing. This work answers specific questions about “ what does a control strategy according to the consistency testing look like” and “ how to submit a control strategy defined according to the consistency testing”. Some topics were answered in a very straightforward manner. This was the case when the deployment of the consistency approach and the corresponding changes in vaccines control strategy was supported by the generic application of procedures already described in regulatory guidelines/requirements and related to the establishment or change in the control strategy of vaccines. The application of other procedures required more specific attention and some were deeply debated before reaching a proposal. The key outcomes of this work are that robust science must be used to develop a substitution strategy and generate supportive data packages. And this good science can best occur with good scientific collaboration between the different parties involved. Therefore, early interaction between manufacturers and competent authorities before and during dossier submission is critical to success. The consistency approach, when approved and in place, will ensure vaccine products of assured quality reach the patient in a more efficient manner than when relying on in vivo testing. Adapting the mindset was one of the major hurdles to a progressive vision but there is now consensus between manufacturers and competent authorities to foster the elimination of in vivo testing for routine vaccine release testing.

1 March 2018 in Biologicals
Verified
Journal Article
Open access
MHMarlies Halder
Marlies Halder
HDHilde Depraetere
Hilde Depraetere
FDFrédérique Delannois
Frédérique Delannois
AAArnoud Akkermans
Arnoud Akkermans
MBMarie-Emmanuelle Behr-Gross
Marie-Emmanuelle Behr-Gross
CSCatrina Stirling
Catrina Stirling
Within the Innovative Medicines Initiative 2 (IMI 2) project VAC2VAC (Vaccine batch to vaccine batch comparison by consistency testing), a workshop has been organised to discuss ways of improving the design of multi-centre validation studies and use the data generated for product-specific validation purposes. Moreover, aspects of validation within the consistency approach context were addressed. This report summarises the discussions and outlines the conclusions and recommendations agreed on by the workshop participants.

1 January 2022 in Talanta
Verified
Journal Article
Closed access
AFAntoine Francotte
Antoine Francotte
RERaphael Esson
Raphael Esson
EAEric Abachin
Eric Abachin
MVMelissa Vanhamme
Melissa Vanhamme
ADAlexandre Dobly
Alexandre Dobly
CVCeline Vanhee
Celine Vanhee

14 February 2009 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
LFLaetitia Forizs
Laetitia Forizs
SLSylvain Lestrade
Sylvain Lestrade
AMAdeline Mol
Adeline Mol
JDJean-Francois Dierick
Jean-Francois Dierick
CGCécile Gerbaux
Cécile Gerbaux
OVOlivier M. Vandeputte
Olivier M. Vandeputte

4 April 2026 in Biologicals
Verified
Journal Article
Open access
SNShawn Novick
Shawn Novick
MBMihai Bilanin
Mihai Bilanin
MBMihaela Buda
Mihaela Buda
NBNermin Buza
Nermin Buza
CFChristopher Carl Frye
Christopher Carl Frye
YTYinying Tao
Yinying Tao
In May 2025, the International Alliance for Biological Standardization (IABS) held a workshop on analytical and bioprocess platforms for biological product development and commercialization. This workshop explored the use of platform approaches and technologies in product development and registration. The topics discussed included the creation, verification, and maintenance of platform technologies, their lifecycle management, their application in regulatory submissions, and the transition from early clinical trials to commercial approval. The participants highlighted the importance of clearly defining the boundaries and applicability of platform approaches in pharmaceutical development. A consistent and open dialogue between industry stakeholders, regulatory reviewers, and health authorities is essential to ensure a shared understanding and alignment in defining the platform landscape.

23 April 2026 in Proteomes
Verified
Journal Article
Open access
PDF file
SKSomar Khalil
Somar Khalil
JDJean-Francois Dierick
Jean-Francois Dierick
PBPascal Bourguignon
Pascal Bourguignon
MPMichel Plisnier
Michel Plisnier
Background: Untargeted proteomics enables quantitative host cell protein (HCP) determination in biotherapeutics, yet no workflow has been validated under ICH Q2(R2) for regulated quality control. Methods: A prospective total-error (TE) validation of label-free ddaPASEF proteomics was performed. A stable isotope-labeled whole-proteome standard was spiked into NISTmAb at seven levels (20–80 ng) and analyzed in four independent assays (198 injections), supporting one-way random-effects ANOVA with Welch–Satterthwaite adjustment. Peptide-level identification error was evaluated by dual entrapment. Results: Empirical false-discovery proportions were below 1% at q = 0.01. Weighted least-squares regression (R2 = 0.993) confirmed stable proportional compression with 81–85% recovery. Repeatability dominated the variance structure (median CV 2.7%); intermediate precision SD ranged from 0.69% to 3.81%. Both 95% β-expectation and 95/95 content tolerance intervals were contained within ±30% at all levels, defining a validated range of 20–80 ng. Abundance-stratified TE profiling revealed concentration-dependent calibration heterogeneity, with stratum-specific intervals within ±35% defining an abundance-aware LLOQ of 3.6 ppm (P95 = 3.87 ppm). Robustness under independent search software (FragPipe v24.0, CCC = 0.998) and cross-platform acquisition (Astral, CCC = 0.980) remained within ±30% limits. Conclusions: This constitutes the first prospective ICH Q2(R2)-aligned validation of untargeted proteomics for HCP quantification, with a transferable statistical framework for high-dimensional analytical methods.